Cardiometabolic
The Novo Nordisk Foundation is going global on cardiometabolic disease.
One of the world’s largest foundations is directing more funding beyond Denmark and making obesity, diabetes and cardiovascular disease a central international priority. The investment could fill a dangerous gap in global health. It also raises a harder question: when public systems underfund chronic disease, how much influence should private philanthropy have over what gets…
Same country, different risks: why Iranian women’s heart disease profiles expose a blind spot in prevention policy
Menopause is a cardiometabolic checkpoint. Health systems still treat it like a hormone debate
GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up
MENA’s cardiometabolic crisis is a stability issue
Corxel’s oral GLP-1 trial adds momentum. The real question is who these drugs will reach
Half of CKM patients go untreated and most fail control
Sleep is now cardiovascular prevention. Health systems still treat it like lifestyle advice
The GLP-1 boom still needs exercise policy
Pharmacists are becoming the front door for cardiometabolic care. Policy is still treating them like the back office
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.